Immunotherapy for recurrent HSV infections

Details Immunotherapy for recurrent HSV infections Immunotherapy for recurrent HSV infections

1992-02-03

1997-10-21

Wax, Robert A.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

4242291, 4352351, 514 12, 530826, A61K 3912, A61K 39245, C07K 14035, C12N 700

Patent

active

056793480

ABSTRACT:
Immunotherapy for the treatment of Herpes Simplex Virus eye infections is disclosed. The invention involves a local therapeutic or prophylactic vaccine for the eye, comprising one or more recombinant HSV-1 glycoproteins or proteins, specifically gB and gD, in combination with at least one adjuvant to reduce the incidence of primary HSV-1 infection and/or decrease spontaneous HSV-1 ocular shedding which in turn, controls recurrent corneal disease.

REFERENCES:
patent: 4891315 (1990-01-01), Watson et al.
patent: 5171568 (1992-12-01), Burke et al.
patent: 5244792 (1993-09-01), Burke et al.
Ghiasi H. et at., High level expression of each of the seven herpes simplex virus glycoproteins in insect cells using baculovirus expression vectors: subsequent use as vaccines, Invest. Ophthalmol. Visual Sci., vol. 32, No. 4, p. 806 (1991) Abstract 686.
Kino Y. et at., Immunogenicity of herpes simplex virus glycoprotein gB-1-related protein produced in yeast, Vaccine, 7:155-160 (1989).
Nesburn A. et al., Efficacy and safety of therapeutic systemic HSV vaccines in the rabbit ocular recurrence model, Invest. Ophthalmol. Visual Sci., vol. 32, No. 4, p. 854 (1991) Abstract 917.
Klein, R.J., Reinfections and site-specific immunity in herpes simplex virus infections. Vaccine, 7:380-381 (1989).
Stanberry, L.R. et al., Herpes simplex virus glycoprotein treatment of recurrent genital herpes. J. Infec. Dis., 157:156-63 (1988).
Kern, A.B. et al., Vaccine Therapy in Recurrent Herpes Simplex. Arch. Derm., 89:844-845 (1964).
Frenkel, L. et al., A randomized double blind, placebo-controlled phase 1 trial of a herpes simplex virus purified glycoprotein (gD1) vaccine. Interscience Conf. on Antimicrobial Agents & Chemo., 206 (1990).
Berman, P.W. et al., Efficacy of Recombinant Glycoprotein D Subunit Vaccines on the Development of Primary, Recurrent, and Latent Genital Infections With Herpes Simplex Virus Type 2 in Guinea Pigs. J. Infec. Dis., 157(5):897-902 (May 1988).
Blacklaws, B. et al., Immunogenicity of herpes simplex type 1 glycoproteins expressed in vaccinia virus recombinants. Virology, 177:727-736 (1990).
Stanberry, L.R. et al., Heterologous Versus Homologous Herpes Simplex Virus Glycoprotein Immunotherapy of Recurrent Genital Herpes. Pediatr. Res., 25:191A, Part 2 (1989).
Rock, D.L., Nesburn, A.B. et al., Detection of latency related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1. J. Virol., 61:3820-26 (1987).
Matsuura, Y. et al., Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins. J. Gen. Virol., 68:1233-50 (1987).
Lee, G.T. et al., Location of the structural genes for glycoproteins gD and gE and for other polypeptides in the S component of herpes simplex virus type 1 DNA. J. Virol., 43:41-49 (1982).
Mathews, J.T. et al., Synthesis and processing glycoprotein D of herpes simplex virus types 1 and 2 in an in vitro system. J. Virol., 48:521-53 (1983).
Ghiasi, H., et al., Cell surface expression of herpes simplex virus type 1 glycoprotein H recombinant baculovirus infected cells. Virology, 185:187-194 (1991).
Morein, B. et al., Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature, 308:457-60 (1984).
Shimormura, Y. et al., Shedding by iontophoresis of 6-hydroxdopamine followed by topical epinephrine. Invest. Ophthalmol., 24:1588-90 (1983).
Nesburn, A.B. et al., Isolation of herpes simplex virus: Isolation from rabbit trigeminal ganglia between episodes of recurrent ocular infection. Arch. Ophthalmol., 88:412-17 (1972).
Nesburn, A.B. et al., Ocular safety and efficacy of an HSV-1 gD vaccine during primary and latent infection. Invest. Ophthalmol. Vis. Sci., 31:77-82 (1990).
Krishna et al (1989) J. gen. Virol. 70 1805-1814.
George et al. (1988) Am. J. Vet. Res. 49 1800-1806.
Miskin et al. Vaccine 9:147-153 (1991).
Kino et al. Arch. Virol. 89:69-80 (1986).
Lucknow et al. (1988) Biotechnology 6:47-55.
Gompels et al (1986) Virology 153:230-247.
Ghiasi, H. et al. Virus Research 22:25-39 (1991).

Affiliated with

Also associated with

Rating

Immunotherapy for recurrent HSV infections does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunotherapy for recurrent HSV infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapy for recurrent HSV infections will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1004610